Celltrion Strengthens Biosimilar Leadership in Key Asian Markets
Celltrion is bolstering its position as a leading biosimilar manufacturer in Asia, achieving significant market share gains for its key products across several countries, including Singapore, Hong Kong, Thailand and Malaysia. The company attributes this success to strategic tender wins, localized sales approaches, and a commitment to supply stability.
Remsima Dominates Infliximab Market
Celltrion’s flagship biosimilar, Remsima (infliximab), continues to demonstrate strong performance in the region. According to data from IQVIA, as of the third quarter of 2025, Remsima holds a commanding 93% market share in Singapore, 77% in Hong Kong, 73% in Thailand, and 65% in Malaysia. Source, Source
Yuflyma Gains Momentum in Autoimmune Disease Treatment
Building on the success of Remsima, Celltrion’s adalimumab biosimilar, Yuflyma, is rapidly gaining traction in the Asian market. In Singapore, Yuflyma has surpassed the original biologic to become the second-most prescribed treatment for autoimmune diseases. Source, Source
To further enhance its competitive edge, Celltrion’s Singapore subsidiary plans to launch a 20mg dosage of Yuflyma, complementing the existing 40mg formulation, ahead of upcoming adalimumab tenders. The company has also recently launched Yuflyma in Malaysia and Thailand. Source
Expanding Oncology Portfolio
Beyond autoimmune diseases, Celltrion’s oncology products are also experiencing increased adoption in key Asian markets. Herzuma (trastuzumab), a treatment for breast and gastric cancer, achieved market shares of 87% in Thailand, 57% in Hong Kong, and 51% in Malaysia as of the third quarter of 2025. Truxima (rituximab), used in the treatment of blood cancer, holds leading positions with 90% market share in Singapore and 79% in Thailand. Source
Strategic Partnerships and Product Pipeline
Celltrion is actively expanding its product portfolio across the region. In Thailand, the company has established long-term partnerships with all university hospitals, where Remsima, Truxima, and Herzuma are now the sole biosimilar options in their respective categories. Source
The company plans to secure approval for Stoboclo-Osenvelt (denosumab) in Singapore this year and introduce three new products – Steqeyma (ustekinumab), Vegzelma (bevacizumab), and Omlyclo (omalizumab) – in Thailand. Source
Commitment to Supply and Market Penetration
A Celltrion official emphasized the company’s commitment to product competitiveness and supply stability in the tender-driven Asian market, stating that new product launches will be executed efficiently to ensure rapid market penetration and increased profitability. Source